2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis
Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes
Sequential compared to upfront treatment of metastatic colorectal cancer using oxaliplatin (Eloxatin) therapy may lead to similar outcomes
Pharma 2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis June 3, 2026
Chronic Disease Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes May 25, 2026
Chronic Disease Sequential compared to upfront treatment of metastatic colorectal cancer using oxaliplatin (Eloxatin) therapy may lead to similar outcomes May 12, 2026
Chronic Disease The incidence of early-onset metastatic adenocarcinoma may be higher among patients with multiple metastatic sites and peritoneal involvement April 30, 2026
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
